The gross margin expansion of over 500 basis points suggests that GKOS is gaining pricing power or benefiting from a favorable product mix, which is a positive signal for future profitability. Operating margin improvement from -45.6% to -9.3% over the same period indicates that revenue growth is outpacing expense growth, a sign of emerging operating leverage. However, the company remains loss-making at the operating level, and the net margin in 2025Q4 was distorted by a large non-operating charge, so investors should focus on operating margin trends rather than net income.

The improvement in ROIC from -3.8% to -1.9% suggests that the company is becoming more efficient at deploying its capital, even though it remains value-destructive. The gap between ROIC and ROE (which was -2.7% in 2026Q2) reflects the impact of leverage and equity issuance, but the trend is positive. The improvement is driven by margin expansion rather than asset turnover, which remains low at 0.20, indicating that the business is asset-light but still scaling. Investors should monitor whether ROIC can turn positive as revenue growth continues.

The cash conversion cycle remains elevated, driven by a high DIO of 163 days and a DSO of 63 days, which suggests that inventory and receivables are tying up significant cash. While the CCC has improved slightly from its peak of 242 days in 2024Q3, it is still well above typical medical device peers, indicating potential inefficiencies in working capital management. The increase in DSO from 46 to 63 days may reflect a shift in customer mix or payment terms, and investors should monitor whether this trend reverses as the company scales.

The dramatic reduction in leverage from 0.85 to 0.15 indicates a strategic deleveraging, likely through debt repayment or equity issuance, which strengthens the balance sheet. Interest coverage is negative due to operating losses, but the lower debt level reduces the risk of covenant breaches and refinancing pressure. The company's ability to service debt is not yet comfortable, but the trend is favorable, and the low D/E ratio provides a cushion for continued investment in growth.

The current ratio of 5.04 and quick ratio of 4.46 suggest that GKOS has ample short-term assets to cover its liabilities, even under stress scenarios. The high liquidity is partly due to the asset-light model and significant cash reserves, which provide a buffer against ongoing operating losses. However, the company is still burning cash in some quarters, so the liquidity position could deteriorate if losses persist, but the current level appears adequate to support the accelerating growth strategy.